Boston Scientific stock advances on strong sales and margin gains
Published on 07/21/2026 at 13:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific (ISIN US10117L1017) is supported by a latest-quarter profile that includes 14.5% revenue growth to $4.1 billion and an adjusted operating margin of 28.7% in the period reported by the company. The stock also carries a market-cap context of $125.2 million in the available data, which gives investors a dated valuation anchor.
Revenue up 14.5%
The latest reported quarter showed revenue of $4.1 billion, up 14.5% from the prior-year period. Adjusted operating margin reached 28.7%, while adjusted EPS came in at $0.62, giving the quarter a clean mix of growth and profitability.
Those figures matter because they show that Boston Scientific stock is not relying on one metric alone. Revenue, margin, and earnings all moved in the same direction in the reported period.
Profitability stays central
Free cash flow was $1.3 billion in the period, while net income reached $725 million, according to the latest company-reported results. The company also said it generated $2.8 billion in operating cash flow, which helps frame the quality of the earnings base.
For investors, the combination of 14.5% revenue growth and 28.7% adjusted operating margin is the more important detail than a single quarter headline. The comparison against the prior-year quarter makes the trend easier to read and keeps the focus on execution.
Quarterly results and company background
Review the latest reported quarter, business segments, and the company profile in one place.
Watch the cash flow
Operating cash flow of $2.8 billion and free cash flow of $1.3 billion are the kind of numbers that can support valuation debates, especially when revenue is still growing at a double-digit rate. The reported net income of $725 million adds another layer to the quarter.
The stock’s broader market context is still tied to whether that growth can persist into later periods. A quarter with 14.5% revenue growth and 28.7% adjusted operating margin gives the company a credible operating base, but the market usually wants repeated proof.
Medical devices drive growth
Boston Scientific's product lineup remains centered on medical devices across cardiovascular, rhythm management, and other interventional categories. That mix matters because the reported revenue growth reflects a broad operating base rather than a single product line.
The company also continues to lean on recurring procedural demand, which helps explain why quarterly revenue can stay resilient. In the reported period, the $4.1 billion revenue figure was the clearest sign that the business remained scaled and active.
Boston Scientific stock at a glance
Boston Scientific stock is linked to the latest reported quarter's $4.1 billion in revenue, $0.62 adjusted EPS, and 28.7% adjusted operating margin. Those numbers give the share a current operating backdrop even without leaning on a price-target story.
The available market-cap context stands at $125.2 million in the source data, which is the only dated market value used here. On that basis, the current lens is the company’s ability to keep turning 14.5% top-line growth into cash and margin.
Boston Scientific stock fact box
- Company: Boston Scientific Corporation
- ISIN: US10117L1017
- Ticker: NYSE: BSX
- Trading venue: NYSE
- Market capitalization: $125.2 million (as of 21 July 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
